Sivertseva S A, Belkin A A, Artem'eva L B, Guseva M E
Tyumen Regional Center for Multiple Sclerosis, Tyumen, Russia.
Clinical Institute of Brain, Berezovsky, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(7. Vyp. 2):73-76. doi: 10.17116/jnevro202012007273.
Alemtuzumab (Lemtrada) is a recombinant humanized IgG1 kappa monoclonal antibody against cell surface glycoprotein CD 52. It is authorized in more than 65 countries worldwide including the Russian Federation. This is one of the most effective drugs for the treatment of the aggressive form of multiple sclerosis. Its safety profile includes different infusion reactions. Current publication demonstrates our experience of using music therapy during alemtuzumab infusion and its role in the adverse reactions management.
阿仑单抗（利妥昔单抗）是一种重组人源化IgG1κ单克隆抗体，可作用于细胞表面糖蛋白CD52。它在包括俄罗斯联邦在内的全球65多个国家获得批准。这是治疗侵袭性多发性硬化症最有效的药物之一。其安全性包括不同的输液反应。当前的出版物展示了我们在阿仑单抗输注过程中使用音乐疗法的经验及其在不良反应管理中的作用。
